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Radiotherapy is the main treatment modality for locally advanced
carcinoma of the cervix (Eifel et al, 1993). However, outcome,
stage for stage, has not changed over the past 25 years and is
particularly poor for later stage disease (Lindegaard et al, 1996). It
has been suggested that a better understanding of the biology of
cervix tumours may lead to the definition of more refined prog-
nostic groups, which in turn may lead to new therapeutic interven-
tions (Kapp et al, 1996). Parameters such as stage and tumour
volume are currently the most established indicators of radio-
therapy response. However, within these prognostic divisions
there is a large variation in response to treatment.
Recently, there has been increased interest in the assessment of
tumour angiogenesis as a potential prognostic factor. This stems
from studies that have established the essential role of angio-
genesis in tumour growth and progression (Folkman, 1990).
Angiogenesis is generally assessed as tumour vascularity, and in
carcinoma of the cervix a number of different measurement tech-
niques have been used. Older studies used inter-capillary distance
(Kolstad, 1968; Awwad et al, 1986) or percentage of endothelial
cells (Siracka et al, 1982) and found that low-vascular density was
significantly associated with poor outcome. However, a recent
consensus statement proposed the intra-tumour microvessel
density (IMD) (‘hot-spot’) technique as the method of choice for
measuring angiogenesis (Vermeulen et al, 1996). Using this tech-
nique, in the majority of studies, high vascularity has been found
to correlate with poor outcome in a number of different tumour
sites including carcinoma of the cervix (Wiggens et al, 1995; Dinh
et al, 1996; Weidner et al, 1996). Using the IMD method, we have
shown recently that patients with well vascularized tumours have
a significantly poorer survival (P = 0.038) and local control
(P = 0.028) than patients with poorly vascularized tumours
(Cooper et al, 1998).
In carcinoma of the cervix, the surviving fraction after 2 Gy
(SF2) has been found not only to be an important predictor of
outcome following radiotherapy, but also to be independent of
other prognostic factors (West et al, 1993, 1997). Based on mathe-
matical modelling it has been proposed that measurements of
tumour radiosensitivity are most likely to correlate with clinical
outcome following radiotherapy (Tucker et al, 1989). It was
suggested, in that paper, that it may be necessary to correct for
intrinsic radiosensitivity before predictive assays based on other
factors might have any clinical significance. The aim of this paper
therefore was to explore the relationship between intrinsic
radiosensitivity and vascularity and to establish whether allowing
for radiosensitivity increased the prognostic significance of vascu-
larity measurements in carcinoma of the cervix.
METHODS AND MATERIALS
Patients
Table 1 summarizes the patient characteristics. Seventy-four
patients with cervical carcinoma undergoing radical radiotherapy
were included in the study. The patients comprised a consecutive
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© 1999 Cancer Research Campaignseries for whom both vascularity and radiosensitivity measure-
ments were available. Patient ages ranged from 23 to 85 years with
a mean of 53 years. The majority of tumours were squamous cell
carcinoma and three were adenocarcinoma. All patients were
included in analyses and the results of the study were unaltered
when the three adenocarcinomas were excluded. Information on
the maximum tumour diameter was only available for 42 of the
patients.
Radical radiotherapy was given according to the doses and
schedules of the Manchester School of Radiotherapy (Hunter,
1991). All patients gave prior informed consent. Follow-up of
patients was 3-monthly in the first 2 years, 4-monthly in the third
year and 6-monthly until 5 years. The median follow-up time in
surviving patients was 86 months, range 28–106. Suspected
tumour recurrence was confirmed either radiologically, histologi-
cally or both.
Measurement of tumour vascularity
Formalin-fixed, paraffin-embedded histological sections, 5-mm
thick, were cut from the biopsy specimens. Samples were stained
for anti-factor VIII (Dako) as previously described (Davidson et
al, 1994). Vascularity was assessed using the ‘hot-spot’ technique
(Weidner et al, 1991). First, the whole tumour section was scanned
at low power (´ 120) to identify the region of most intense neovas-
cularization. Within this region the number of vessels in three
separate random fields were counted at high power (´ 25 objective
and  ´ 12 ocular; field size 0.142 mm2). The mean number of
vessels from the three fields was used in the analysis. Any brown-
staining endothelial cell or group of cells, clearly separate from
adjacent tumour or stromal cells, was considered a single count-
able vessel. Areas of gross haemorrhage or necrosis were avoided.
Scoring was performed by a single observer without prior
knowledge of patient outcome. Intra-observer reproducibility was
assessed by scoring ten randomly chosen sections twice. Inter-
observer variability was assessed by scoring 20 randomly chosen
sections by two independent scorers.
Measurement of tumour radiosensitivity
Intrinsic radiosensitivity was determined as sensitivity to a single
in vitro 2 Gy dose of radiation (SF2). Tumour was disagreggated
using an enzyme cocktail prior to irradiation with a 137Cs g-source
at a dose rate of 3.8–4.2 Gy min–1. Single-cell suspensions were
cultured using a soft agar clonogenic assay and the SF2 calculated
from the colony forming efficiencies of control or irradiated
samples after 4 weeks growth (West et al, 1993). Characterization
of cells growing in colonies was carried out using immunohisto-
chemistry with CAM5.2 and CK1 antibodies to confirm that the
colonies grown were of malignant epithelial cell origin (West et al,
1993).
Statistics
The relationship between variables was investigated using
Spearman’s correlation coefficient. Overall survival and local
control probabilities were determined using univariate and
bivariate (stratified) log-rank analysis, stratifying by the parameter
medians. Values falling on medians meant that the numbers in each
group were unequal. A step-wise Cox multivariate regression
analysis was also performed. A significance level of P = 0.05 was
used throughout.
RESULTS
Vascularity and outcome
Using the IMD technique we have previously shown a high level
of correlation between repeat measurements by the same (r = 0.84,
P = 0.04), and two independent (r = 0.88, P < 0.0001) scorers
(Cooper et al, 1998). The median IMD for the 74 patients was 10
(range 2–32). Patients were stratified into two groups, those with a
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Table 1 Patient characteristics
Characteristics Number
Stagea I2 4
II 31
III 19
Histology SCCb wellc 13
modc 41
poorc 17
Adenod 3
Maximum diameter < 4 cm 20
³ 4c m 2 2
aAccording to the FIGO staging system. bSquamous cell carcinoma. cWell,
moderately and poorly differentiated. dAdenocarcinoma.
Table 2 Cox multivariate analysis showing the relative risk (RR) for 74
cervix tumours
Survival Local Control
Variable RR (95% CI) P RR (95% CI) P
SF2 3.9 (1.8–8.4) 0.001 3.7 (1.4–9.8) 0.008
IMD 2.7 (1.3–5.6) 0.007 3.2 (1.2–8.4) 0.017
Age NS 0.079 NS 0.96
Stage NS 0.90 NS 0.57
NS = not significant.
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Figure 1 The relationship between SF2 and IMD for 74 patients with
carcinoma of the cervix356 RA Cooper et al
British Journal of Cancer (1999) 81(2), 354–358 © 1999 Cancer Research Campaign
mean IMD > 10 (high vascularity tumours) and those with a mean
IMD ≤ 10 (low vascularity tumours). The 5-year survival rate for
patients with low vascularity tumours was 77% compared to 44%
for those with high vascularity tumours (P = 0.035). The 5-year
local control rate was 83% and 65% for patients with low and high
vascularity tumours respectively (P = 0.077).
SF2 and outcome
The median SF2 value for the 74 patients was 0.42 (range
0.14–0.82). Patients were divided into those with radiosensitive
tumours, SF2 ≤ 0.42 and those with radioresistant tumours
SF2 > 0.42. Patients with radiosensitive tumours had a signifi-
cantly higher 5-year survival rate of 74% compared to 37% for
those with radioresistant tumours (P = 0.0005). There was also a
significant difference in the 5-year local control rate of 85% and
63% for patients with radiosensitive and radioresistant tumours
respectively (P = 0.012).
Relationship between tumour vascularity and intrinsic
radiosensitivity
Figure 1 shows the lack of correlation between measurements of
IMD and SF2 in the same patient (r = 0.17, P = 0.15). In order to
further check for the independence of the two parameters,
bivariate log-rank analyses were carried out. Patients were strati-
fied according to the median value for IMD after allowing for SF2
(Figures 2 and 3). The prognostic power of the IMD measurements
increased and the overall significance levels for survival and local
control were 0.006 and 0.013 respectively. Multivariate Cox
regression analyses were also carried out which included: disease
stage, patient age, SF2 and IMD (Table 2). SF2 emerged as the
most important prognostic variable and after allowing for it only
IMD was significantly associated with treatment outcome.
Additional Cox analyses were made on a small subset of 42
patients for whom tumour grade and volume information were also
available. For overall survival, IMD emerged as the most impor-
tant prognostic parameter (relative risk (RR) of 5.2, P = 0.022) and
after allowing for it only patient age was significant (RR of 3.1,
P = 0.031). SF2 showed borderline significance (P = 0.092). For
local control, SF2 was the most important parameter (RR of 3.8,
P = 0.016) and after allowing for it, only IMD was significant (RR
of 5.2, P = 0.031).
Although stage is often a powerful prognostic indicator for
outcome, in this group of patients it was only of borderline signifi-
cance for survival (P = 0.085) in univariate analysis but not signif-
icant on multivariate analysis. Stage was not a significant
prognostic factor for local control in univariate or multivariate
analysis.
Combining IMD and SF2 measurements
As measurements of IMD and SF2 are completely independent, it
is possible to combine the two factors and identify patients with
good versus poor prognosis. In patients with radiosensitive
tumours, there was no difference in survival for patients with low
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Figure 2 Survival in respect to vascularity for: (A) patients with
radiosensitive tumours and (B) patients with radioresistant tumours. The
values above each arm of the graph indicate the number of deaths/patients
in each group. Patients were stratified by the overall median values for both
SF2 (of 0.42) and vascularity (of 10)
Figure 3 Local control in respect to vascularity for: (A) patients with
radiosensitive tumours and (B) patients with radioresistant tumours. The
values above each arm of the graph indicate the number of local
recurrences/patients in each group. Patients were stratified by the overall
median values for both SF2 (of 0.42) and vascularity (of 10)Vascularity and radiosensitivity in cervix tumours 357
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and highly vascular tumours (Figure 2). However, for patients with
radioresistant tumours vascularity was very important (Figure 2).
The 5-year survival levels for patients with radiosensitive and
poorly vascularized versus radioresistant and well vascularized
tumours were 77% and 18% respectively. Similarly, the 5-year
local control levels for patients with radiosensitive and poorly
vascularized versus radioresistant and well vascularized tumours
were 90% and 50% respectively.
DISCUSSION
Tumour vascularity measured as IMD has been shown by us to be
a significant and independent prognostic factor for survival and
local control following radiotherapy in 111 cervix cancer patients
(Cooper et al, 1998). A smaller subset of 74 patients was studied
here representing the 67% of patients for whom SF2 data were
obtained. Reasons for not obtaining radiosensitivity results were
either insufficient biopsy material or poor tumour growth in the
assay. The smaller subset was representative of the larger study
except that IMD was only of borderline significance for local
control. This latter finding is probably due to the smaller number
of patients included in the present study. The value of tumour SF2
as an independent prognostic factor for outcome following radio-
therapy has been previously documented by us in 128 women with
carcinoma of the cervix (West et al, 1993, 1997). The smaller
cohort of 74 patients studies here was also representative of the
larger group as SF2 was significantly associated with both survival
and local control. The independence of the two biological parame-
ters was shown in regression, bivariate log-rank and Cox multi-
variate analyses.
Although divergent mechanisms underlie inter-individual
differences in tumour vascularity and radiosensitivity it is also
possible that some common factors influence both parameters.
Tumour angiogenesis is thought to be regulated by a balance
between angiogenic promoters and inhibitors (Hanahan et al,
1996). Inter-tumour heterogeneity is a reflection of the positive
and negative local effects of tumour, stromal and inflammatory
cells acting in a paracrine fashion (Folkman, 1996). Tumour
angiogenesis is stimulated by a number of growth factors
including vascular endothelial growth factor (VEGF), basic and
acidic growth factor and platelet-derived growth factor amongst
others (Weidner et al, 1996), which in turn may be stimulated by
local tumour characteristics such as hypoxia (Schweiki et al, 1992;
Kuwabara et al, 1995). Furthermore, endothelial cells can stimu-
late the growth of tumour cells by the production of growth factors
such as platelet-derived growth factor, insulin-like growth factor
and interleukin-6 (Folkman, 1996). Hypoxia is also an important
factor influencing cellular radiosensitivity (Thomlinson, 1968)
and determining radiotherapy response (Hockel et al, 1996). The
tumour suppressor gene, TP53, is another important modifier of
intrinsic radiosensitivity (Bristow et al, 1996). It is of interest to
note, therefore, that loss of wild-type p53 has been shown to
down-regulate the angiogenesis inhibitor, thrombospondin-1
(Dameron et al, 1994) and up-regulate VEGF (Rak et al, 1997).
Although IMD and SF2 are independent prognostic parameters,
individual heterogeneity in tumour radiosensitivity dominates the
differences in radiocurability seen for the cervix cancer patients
studied here. This finding supports the results of a mathematical
modelling study comparing clonogen number, radiosensitivity,
hypoxia and proliferation measurements as predictors of radio-
therapy response (Tucker et al, 1989). In Tucker’s paper, SF2 was
shown to dominate differences in radiocurability such that ‘it may
be necessary to correct for individual differences in intrinsic
radiosensitivity before predictive assays based on other tumour
characteristics might have any detectable clinical significance’.
The main reason behind this is probably because the effect of SF2
is magnified over a course of protracted radiotherapy. For
example, for a treatment involving 30 ´ 2 Gy fractions, tumours
with mean SF2 values of 0.38 and 0.54 will have final differences
in surviving fractions of around 10–8 and 10–12 respectively (Rak et
al, 1997). In the work reported here we have shown that allowing
for tumour SF2, increases the prognostic significance of IMD
measurements. In addition, we have already shown a similar effect
for patient age, tumour size and p53 expression (West et al, 1995).
Finally, we have shown the potential of combining two indepen-
dent prognostic factors to define groups with large differences in
outcome probabilities. Clearly, IMD appears more significant for
radioresistant tumours. Therefore trials of anti-angiogenic
chemotherapy could be directed at patients with radioresistant
tumours, which would increase any chance of detecting a clini-
cally significant difference.
In conclusion, the work reported here has shown no relationship
between measurements of vascularity and radiosensitivity in the
same tumour, and that allowing for SF2 increases the prognostic
significance of IMD. This study emphasizes the potential of
combining biological prognostic information to provide highly
significant differences in radiotherapy outcome probabilities that
may be of future clinical use to individualize patient treatment.
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